Aim: Stage II-IV colorectal cancers are subdivided according to TNM categories. However, stage I cases are a single category, despite the inclusion of both T1 and T2 cases, which may have different outcomes. The aim of this study was to evaluate the usefulness of subdividing stage I colorectal cancers by T category.
Methods: From 1984 to 2015, 844 patients with stage I colorectal cancer (T1: 446, T2: 398) underwent colorectal resection with lymph node dissection at three hospitals. The long-term survival and recurrence rates were compared between T1 and T2. A Cox regression analysis was used to evaluate the risk factors associated with cancer recurrence.
Results: A comparison of the T1 and T2 groups revealed significant differences in 5-year overall (95.9% vs 91.4%, = .008), recurrence-free (94.8% vs 87.1%, = .0007), and cancer-specific survival (97.6% vs 93.6%, = .004), and in the overall (2.5% vs 6.8%, = .003), local (0.2% vs 1.5%, = .04), and lymph node recurrence rates (0.2% vs 1.5%, = .04). All local and lymph node recurrences were associated with lower rectal cancer, and this difference was significant. The Cox multivariate analysis identified male sex ( = .01, hazard ratio: 4.00, 95% confidence interval: 1.38-11.55), T2 ( = .02, hazard ratio: 2.98, 95% confidence interval: 1.17-7.60), and venous invasion ( = .03, hazard ratio: 2.38, 95% confidence interval: 1.12-5.10) as risk factors for recurrence.
Conclusions: The subdivision of stage I colorectal cancer according to T category clearly reflected the long-term outcomes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034690 | PMC |
http://dx.doi.org/10.1002/ags3.12407 | DOI Listing |
J Invest Surg
January 2025
Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Background: The prognostic value of tumor regression grade (TRG) after neoadjuvant chemoradiotherapy for rectal cancer is inconsistent in the literature. Both TRG and post-therapy lymph node (ypN) status could reflect the efficacy of neoadjuvant therapy. Here, we explored whether TRG combined with ypN status could be a prognostic factor for MRI-based lymph node-positive (cN+) rectal cancer following neoadjuvant chemoradiotherapy.
View Article and Find Full Text PDFDig Dis Sci
January 2025
Department of Public Health, Erasmus University Medical Center, Rotterdam, Netherlands.
Background: Development of novel colorectal cancer (CRC) screening tests is a dynamic field. Decision analytic modeling based on inputs derived from rigorous prospective studies informs CRC screening guidelines. Exploratory modeling may have a place in early phases of test development.
View Article and Find Full Text PDFBMJ Open Gastroenterol
January 2025
Department of Gastroenterology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Objective: Studies in the USA examining the relationship between ethnicity and colorectal cancer (CRC) identified significant variation. This study sought to examine the relationship between ethnic group, route to diagnosis, early-onset CRC and stage at diagnosis in the English National Health Service.
Methods: Data from COloRECTal cancer data Repository for all individuals diagnosed with CRC (International Classification of Diseases version 10, C18-C20) between 2012 and 2017.
Public Health
January 2025
Danish Centre for Health Economics, University of Southern Denmark, Denmark. Electronic address:
Objectives: This Danish nationwide retrospective register-based cohort study investigated healthcare costs for patients with screen-detected colorectal cancer (SD-CRC) compared to non-screen-detected CRC (NSD-CRC).
Study Design: Nationwide cohort study.
Methods: Quarterly healthcare costs including costs of hospital care, out-of-hospital medication, and primary sector contacts were compared between the two groups from two years before diagnosis of CRC until two years after.
Cancer Med
January 2025
Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada.
Background: Adults with intellectual or developmental disability (IDD) are at higher risk for incomplete cancer staging.
Aim: To compare unknown stage data between those with and without IDD.
Materials And Methods: We used the Ontario Cancer Registry linked to administrative health data between 2007 and 2019.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!